Tanabe Pharma America, Inc.

This study aimed to test if an oral version of the drug edaravone could help slow the progression of ALS over 48 weeks. It involved 384 adults recently diagnosed with ALS who showed a specific rate of decline in their physical abilities. The trial was terminated early, so its fin…

This study aimed to see if continuing an oral medication called edaravone for up to 48 more weeks could help slow the progression of ALS (amyotrophic lateral sclerosis) in people who had already completed a previous trial. It involved 202 participants and compared two different d…

This was an early-stage study to check the safety and see how the body processes a new, unnamed drug called MT-6345. It involved 52 healthy volunteers who received either the drug or a placebo. The main goal was to see what side effects occurred and to measure how the drug moved …